



NATIONWIDE INCIDENCE RATE

1 IN 8 MEN
will be diagnosed with
prostate cancer in their lifetime

3.3+ MILLION MEN
currently diagnosed with prostate cancer

This year in the United States:
New cases: **299,010** | Deaths: **35,250**

VETERANS ARE 1.5X
more likely to get prostate cancer

AFRICAN AMERICAN MEN ARE 2.1X
more likely to die of prostate cancer.

INCIDENCE RATE IN DELAWARE

125 IN EVERY 100,000 MEN
will be diagnosed with
prostate cancer in their lifetime

18.9 IN EVERY 100,000 MEN
die from the disease

This year in Delaware:
New cases: **1,320** | Deaths: **170**

NATIONAL RANKINGS BY STATE:

#10 for prostate cancer incidence
#35 for prostate cancer deaths

Source: Estimates based on 2024 data from the American Cancer Society

ZERO's Impact in Delaware

Patient Programs

- **ZERO360** is a free, comprehensive support service that helps patients and their loved ones navigate insurance, find resources to help pay for treatment and living expenses, connect with emotional support services, and ensure access to care.
- **ZERO's nationwide Us TOO support group network** offers a variety of peer-led virtual and in-person groups offering emotional support, resources, and education to empower those impacted by prostate cancer to make informed decisions about their care.
- **ZERO's MENtor program** matches patients with trained, volunteer MENtors who have been on a similar journey to provide ongoing, one-on-one support.
- **ZERO Connect** is our online private Facebook group where you can connect with others affected by prostate cancer, ask questions, and learn from their experiences.

CDMRP* Grants in Delaware

Year Introduced: 1997

Total Grants to Date: 12

Total Grand Awards Through FY 2022:** \$3.8M

* Congressionally Directed Medical Research Programs

**PCRP (Prostate Cancer Research Program) data for FY 2023 has not yet been posted

GRANT RECIPIENT	YEAR	AMOUNT
Nemours Biomedical Research Delaware	2003	\$568,200
University Of Delaware	2007	\$546,169
	2004	\$558,731
	2000	\$533,202
	1999	\$375,398

CDC's National Comprehensive Cancer Control Program (NCCCP) Funding in Delaware:

- **GOAL 1:** Continue the Cancer Screening Nurse Navigator program to promote colorectal, prostate, breast, and cervical cancer screening. Total cost for this Goal over the 5 year period of this plan: \$7,500,000.
- **Objective 1B:** Achieve a 50% increase in the number of men 50-75 (or life expectancy of 10 years) and high-risk men starting at age 40 reporting that they have discussed prostate cancer screening with a health care provider.
- **Task/action:** Determine baseline number of men 50-75 (or life expectancy of 10 years) and high-risk men starting at age 40 reporting that they have discussed prostate cancer screening with a health care provider (year 1). Increase dissemination of DCC prostate cancer screening recommendations to health care providers (year 1 and ongoing). Reevaluate data received regarding men 50-75 (or life expectancy of 10 years) and high-risk men starting at age 40 reporting that they have discussed prostate cancer screening with a health care provider (year 2 and ongoing).
- **GOAL 2:** Reimburse colorectal, prostate, breast, and cervical cancer screening for Delawareans who meet age and income eligibility guidelines. Total cost for this Goal over the 5 year period of this plan: \$3,469,900.

(continued from previous page) CDC's National Comprehensive Cancer Control Program (NCCCP) Funding in Delaware:

- **OBJECTIVE 2A:** Continue annual allocation for colorectal, prostate, cervical, and breast cancer screening for men and women ineligible for federally funded screening.
- **Task/action:** Reimburse providers through the Screening for Life program for services for cancer screening for men and women.
- **OBJECTIVE 2B:** Add continued surveillance as a Screening for Life-covered service for clients served through the Delaware Cancer Treatment Program.
- **Task/action:** Determine acceptable surveillance procedures for coverage. Allocate annual allotment of SFL funding to cover surveillance procedures for patients diagnosed with cancer who have income between 251% and 650% of the Federal Poverty Level. Revise allocation based on actual costs and projections.

ZERO Prostate Cancer is the leading national nonprofit with the mission to end prostate cancer. ZERO advances research, improves the lives of men and families, and inspires action. Visit our website: www.zerocancer.org.

ZERO Contact:

Ali Manson, MPH
Vice President, Government Relations & Advocacy
ali@zerocancer.org | 703-624-1223



ZERO is a 501(c)(3) philanthropic organization recognized with four out of four stars by Charity Navigator and is accredited by the Better Business Bureau.